Omaha, Nebraska and Orlando, Florida Will Host Pool Play,

With Anaheim, California Hosting the Quarterfinal, Semifinal, and Final Matches

LAUSANNE, Switzerland, Sept. 17, 2026 /PRNewswire/ -- The FIVB today revealed the American host cities and venues for the 2027 FIVB Women's Volleyball World Cup, the sport's flagship international tournament. The United States and Canada were announced as host nations in September 2025. Anaheim, California (Honda Center), Omaha, Nebraska (CHI Health Center Arena), and Orlando, Florida (Kia Center) will be among the host cities for the 32-nation tournament. An announcement on the Canadian host cities will follow.

Host cities and venues were selected based on passionate fan bases, world-class venues with seating capacities worthy of a World Cup, strong government and local partner support to ensure exceptional experiences, and markets that can attract new fans and accelerate volleyball's growth across North America.

The Women's Volleyball World Cup will run August 20 – September 5, 2027. Omaha and Orlando will host Pool Play and round-of-16 matches. The Honda Center in Anaheim will host the quarters, semis, and finals in 2027, and then serve as the host venue for the men's and women's indoor volleyball competition for the LA28 Games. Each city brings unique attributes and experiences designed to make this first-ever Women's Volleyball World Cup a spectacle beyond anything the sport has seen before.

"USA Volleyball, Volleyball Canada, and the WVWC27 Local Host Committee are proud to announce a series of 'firsts' for the sport in North America," said Craig Thompson, CEO of the WVWC27 Local Host Committee. "The most modern and professional sport venues to ever host this event, 57 hours of live match and studio coverage, and the finals week at the spectacular OCVIBE district. This World Cup will elevate volleyball in North America to the top level of women's sports, where it belongs."

The Women's Volleyball World Cup arrives in the United States and Canada at a moment of explosive growth for women's volleyball at every level. As the sport's premier international event makes its debut in North America next summer, it will amplify that growth while marking a key step on the road to LA28. The tournament's new format has further raised the stakes, turning it into an Olympic Qualifier, with the top three national teams not yet qualified for the LA28 Games earning their spots. With the Women's Volleyball World Cup taking place just weeks after the FIFA Women's World Cup, 2027 is shaping up to be a landmark year for sports.

ION, E.W. Scripps Company's national sports and entertainment network, will provide 17 days of national coverage, including 19 live matches on national broadcast, 10 hours of studio show coverage, and stream 45 matches. Ticket pricing will be announced in mid-October when the pools are announced. For fans looking to be first in line for news and offers, please visit www.wvwc27.org for more information and sign up now.

SOURCE FIVB Women's Volleyball World Cup

Share this article

Passenger Trips Up 5% Year Over Year, Surpassing 25 Million

ARLINGTON, Va., Sept. 17, 2026 /PRNewswire/ -- Today, Airlines Reporting Corporation (ARC) released data showing U.S.-based travel agency air ticket sales total $9.8 billion in August 2026 — a 19% increase from August 2025, the previous highest recorded August total.* Passenger trips reached 25.8 million in August 2026, a 5% year-over-year increase.

Results for August 2026 showed:

"August's totals set a new record for ARC-reported and settled sales, reflecting the continued strength of the U.S travel market and continued demand," said Steve Solomon, ARC's Chief Commercial Officer. "The strong summer trends from June and July carried into August, with travel to both U.S. domestic and international destinations remaining steady from the prior month and above 2025 levels."

NDC transactions accounted for 21.5% of total ARC-settled transactions in August 2026, which is a 3% increase from the previous year. In August 2026, 1,221 travel agencies reported NDC transactions.

More detailed information is available on ARC's sales statistics page.

About ARC:

ARC's platform is the intelligence behind air travel, connecting the industry and powering commercial decisions for airlines and their partners. Our trusted services fuel airline retailing, with ARC processing over $100 billion in U.S.-based agency air sales annually. ARC leads industry collaboration between airlines, agencies, corporate buyers and other partners to enable a thriving industry ecosystem. For more information, visit arccorp.com.

Contact: 

ARC Media Team

[email protected]

Notes:

*Ticket Sales

- Results are based on monthly sales data ending August 31, 2026, from 9,879 U.S. retail and corporate travel agency locations and online travel agencies. Results do not include sales of tickets purchased directly from airlines.

- The average ticket price (USD) is for a round-trip ticket settled through ARC for an itinerary that included only U.S. domestic travel.

- Passenger trips include the total number of passengers traveling from one airport to another using direct or connecting flights. Newly issued trips are added, and refunded trips are deducted to provide a net view of traveling passengers.

- U.S. domestic passenger trips include the total number settled through ARC where the itinerary is wholly within the U.S. International passenger trips include the total number settled through ARC where some or all the travel occurs to airports outside the U.S. or originates outside the U.S.

- Total sales are equal to the total amount paid for a ticket, which includes taxes and fees.

**Average Economy Class Ticket Price

- Economy Class is defined as tickets for U.S. domestic travel purchased in August 2026 under fare codes excluding First Class, Business Class and Business Class Premium.

***Average Premium Class Ticket Price

- Premium Class is defined as tickets for U.S. domestic travel purchased in August 2026 under fare codes assigned to First Class, Business Class and Business Class Premium.

© Airlines Reporting Corporation (ARC). All rights reserved.

SOURCE Airlines Reporting Corporation (ARC)

Share this article

The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceuticals), KP104 (Kira Pharmaceuticals), and others may increase the paroxysmal nocturnal hemoglobinuria market size in the coming years, assisted by an increase in the diagnosed prevalent population of PNH.

LAS VEGAS, Sept. 17, 2026 /PRNewswire/ -- Until 2007, paroxysmal nocturnal hemoglobinuria (PNH) was a life-threatening disorder with limited therapeutic options for controlling hemolysis and thrombosis, the latter being a major contributor to mortality. The treatment landscape underwent a significant transformation with the introduction of the anti-C5 complement inhibitor eculizumab, which substantially reduced hemolysis, lowered transfusion requirements, and, importantly, decreased the risk of thrombosis.

The current disease-modifying treatment approach for PNH is centered on complement inhibition. FDA-approved therapies, including SOLIRIS (eculizumab), ULTOMIRIS (ravulizumab), and EMPAVELI (pegcetacoplan), have established complement inhibition as the standard of care. However, limitations and safety considerations associated with terminal complement inhibition have driven the development of alternative therapeutic approaches. More recent approvals of proximal complement inhibitors, including FABHALTA (iptacopan), VOYDEYA (danicopan), and PIASKY (crovalimab), are expanding treatment options and aim to provide more effective disease control while addressing limitations associated with existing therapies.

Find out the future of the paroxysmal nocturnal hemoglobinuria PNH treatment market @ https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market

The PNH pipeline continues to evolve, with emerging candidates such as Zaltenibart (OMS906), pozelimab, and ruxoprubart (NM8074), among others, highlighting ongoing innovation and the growing diversity of complement-targeted treatment strategies.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among the emerging therapies, Pozelimab is expected to generate the highest revenue in the 7MM, followed by Zaltenibart. In a Phase II study, Zaltenibart demonstrated strong efficacy in PNH patients with suboptimal responses to ravulizumab.

Reflecting continued therapeutic innovation and significant unmet medical needs, DelveInsight estimates that the paroxysmal nocturnal hemoglobinuria market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 1.5 billion in 2025. The market is projected to expand at a CAGR of 7.1% during the forecast period through 2036, driven by the introduction of novel complement-targeted therapies, advances in disease management, increasing awareness and diagnosis of PNH, and ongoing efforts to address breakthrough hemolysis, transfusion dependence, and other limitations associated with existing treatments.

Below, we highlight 5 promising emerging therapies poised to reshape the future of the paroxysmal nocturnal hemoglobinuria market.

Regeneron Pharmaceuticals' Pozelimab + Cemdisiran

C5 complement inhibitor

Pozelimab is an investigational fully human monoclonal antibody engineered to inhibit complement component C5, thereby preventing the destruction of red blood cells associated with paroxysmal nocturnal hemoglobinuria (PNH) and other disorders driven by complement pathway activation. As an IgG4 antibody, pozelimab binds with high affinity to both wild-type and variant forms of human C5, blocking its biological activity.

Pozelimab was developed using Regeneron's proprietary VelocImmune® technology, which employs a genetically humanized mouse platform to generate optimized fully human antibodies. The technology enables the efficient and direct identification of multiple antibody drug candidates from immunized mice. By overcoming limitations associated with conventional antibody-generation approaches, VelocImmune facilitates the rapid development of fully human antibodies with strong target binding while minimizing the potential for immune reactions associated with antibodies containing nonhuman, typically murine, components.

As part of its broader clinical development program, pozelimab is also being investigated in combination with cemdisiran, Alnylam's small interfering RNA (siRNA) therapy targeting complement C5, for the treatment of additional complement-mediated disorders, including PNH and myasthenia gravis (MG). Regeneron Pharmaceuticals has reported that results from the Phase III study evaluating the pozelimab–cemdisiran combination in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027.

Novo Nordisk's Zaltenibart (OMS906)

MASP-3 inhibitor

Zaltenibart (OMS906), a lead monoclonal antibody designed to target mannan-binding lectin-associated serine protease-3 (MASP-3), a key activator of the alternative complement pathway, is currently being evaluated in Phase II clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy (C3G). In a single-ascending-dose Phase I study conducted in healthy participants, zaltenibart demonstrated a favorable safety and tolerability profile, with no significant safety concerns reported. The therapy has also received Orphan Drug Designation (ODD) from the FDA for the treatment of PNH.

In November 2025, Omeros Corporation announced the completion of an asset purchase and license agreement with Novo Nordisk, under which Novo Nordisk obtained exclusive worldwide rights to develop and commercialize zaltenibart, formerly known as OMS906, across all indications. The transaction transferred the global development and commercialization rights for the human monoclonal antibody targeting MASP-3 to Novo Nordisk.

Discover more about the new treatment options for paroxysmal nocturnal hemoglobinuria @ Paroxysmal Nocturnal Hemoglobinuria Treatment Market

NovelMed Therapeutics's Ruxoprubart (NM8074)

Complement C3–C5 convertases inhibitor

Ruxoprubart (NM8074) is an anti-Bb monoclonal antibody designed to selectively inhibit the complement alternative pathway while preserving the classical pathway, which remains essential for effective infection clearance. The therapy completed a Phase I clinical trial involving 40 healthy volunteers, demonstrating a favorable safety and tolerability profile across all tested doses. Complete inhibition of the alternative pathway was achieved, with the duration of inhibition increasing in a dose-dependent manner.

Ruxoprubart is currently being evaluated in a Phase II clinical trial in treatment-naive patients with paroxysmal nocturnal hemoglobinuria, where it has demonstrated encouraging results to date. Beyond PNH, the therapy may also have potential across other clinical indications associated with dysregulation of the complement alternative pathway.

Kira Pharmaceuticals' KP104

Complement C5 inhibitors; Complement factor H inhibitors

KP104 is a first-in-class bifunctional biologic engineered to simultaneously inhibit the alternative complement pathway through Factor H and the terminal pathway through C5. By targeting both pathways, KP104 is designed to deliver a potent and synergistic approach to addressing established drivers of complement-mediated diseases. This dual mechanism differentiates KP104 from single-target complement therapies and may offer broader therapeutic benefits across complement-related disorders.

KP104 has been engineered for an extended half-life and increased potency, with a formulation that supports both intravenous and subcutaneous administration. The therapy is advancing into Phase II proof-of-concept studies across multiple renal and hematologic indications. The U.S. FDA has also granted KP104 Orphan Drug Designation for the treatment of paroxysmal nocturnal hemoglobinuria. Phase II clinical development is planned globally, including in the United States, China, and Australia. KP104 remains an investigational therapy and has not yet received regulatory approval for any indication from any health authority.

To know more about paroxysmal nocturnal hemoglobinuria drug development, visit @ Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline

NovelMed Therapeutics's NM5072

Properdin inhibitors

NovelMed is developing NM5072, a monoclonal antibody that has completed a Phase I clinical trial for paroxysmal nocturnal hemoglobinuria. Preclinical studies in animal models have demonstrated the therapy's potential across hematological, inflammatory, and ocular disease indications, while extensive evaluations have also been conducted using serum and blood samples from patients with PNH. NM5072 has received Orphan Drug Designation (ODD), and Phase II INDs have been approved for both hematological and renal indications.

Download the report to understand the top emerging therapies in PNH treatment @ Paroxysmal Nocturnal Hemoglobinuria Clinical Trials

Source: Paroxysmal Nocturnal Hemoglobinuria Market Report

Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNH companies, including Alexion Pharmaceuticals, AstraZeneca, Apellis Pharmaceuticals, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, NovelMed Therapeutics, ADARx Pharmaceuticals, Kira Pharmaceuticals, and others.

Related Reports

Complement Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key complement inhibitors companies including AstraZeneca, Annexon, Inc.

SHERIDAN, Wyo., Sept. 17, 2026 /PRNewswire/ -- The global in vitro diagnostics market is projected to grow from USD 117.39 billion in 2026 to USD 170.10 billion by 2031, registering a CAGR of 7.7% during the forecast period (2026–2031), according to a new study by Wissen Research.

Growth is being driven by rising demand for early disease detection, accurate diagnosis, disease monitoring, and personalized healthcare. Increasing prevalence of chronic and infectious diseases, growing adoption of point-of-care testing, and continued advances in molecular diagnostics, immunoassay, and clinical chemistry technologies are improving the speed, accuracy, and efficiency of diagnostic testing across hospitals, diagnostic laboratories, and home-care settings.

Get a Free Sample of This Report to Explore Key Findings and Data:

Where Diagnostic Testing Is Heading: Molecular Platforms and Decentralized Testing

Among all IVD technology categories, molecular diagnostics stands out as the clear growth engine — projected to register the fastest CAGR of any technology segment at approximately 14.7% through 2031. PCR, next-generation sequencing, isothermal nucleic acid amplification, and other nucleic acid-based techniques are enabling detection of pathogens, genetic abnormalities, and disease biomarkers at a level of sensitivity conventional testing methods cannot match, with expanding applications across infectious disease testing, oncology, and genetic and personalized medicine.

At the same time, testing is moving out of the centralized lab and closer to the patient. Point-of-care testing and portable diagnostic platforms are enabling faster clinical decision-making in hospitals, emergency departments, and home-care settings alike, supported by continued advances in multiplex testing, laboratory automation, and digital diagnostics that let a single platform screen for multiple conditions simultaneously.

What's Fueling Growth in the In Vitro Diagnostics Market

- Rising Chronic and Infectious Disease Burden: Growing global prevalence of cancer, diabetes, cardiovascular disease, and respiratory infections is driving sustained demand for diagnostic testing.

- Point-of-Care Testing Adoption: Rapid diagnostic solutions are enabling faster clinical decision-making across hospitals, laboratories, emergency settings, and home-care environments.

- Molecular and Immunodiagnostic Advances: Progress in PCR, sequencing, chemiluminescence, and fluorescence-based technologies is improving testing sensitivity, specificity, and speed.

- Expanding Healthcare Expenditure: Rising global healthcare spending and growth in diagnostic laboratory infrastructure are supporting broader IVD adoption.

- Personalized Healthcare and Companion Diagnostics: Increasing use of IVD technologies in biomarker analysis and companion diagnostics is expanding the category's role in precision medicine.

- AI Integration in Diagnostics: Growing use of artificial intelligence and digital pathology tools is improving laboratory workflow efficiency and diagnostic accuracy.

Challenges Facing the In Vitro Diagnostics Market

Bringing a new diagnostic test to market remains a costly and technically demanding process. High research and development costs, stringent regulatory requirements, and complex reimbursement pathways continue to slow product launches, while maintaining consistent accuracy, sensitivity, and specificity across large-scale manufacturing adds further technical complexity. The shift toward digital and connected diagnostics is also raising data management and cybersecurity considerations for laboratories and healthcare providers, and the field continues to face a shortage of specialized technical expertise needed to run advanced molecular and automated testing platforms.

Recent Strategic Developments in the In Vitro Diagnostics Market

In July 2026, Siemens Healthineers launched a new core-lab capillary testing menu on its Atellica CH, IM, and CI analyzers following CE marking for 24 capillary blood testing claims, expanding the Atellica portfolio to include metabolic, lipid, thyroid, Vitamin D, and HbA1c testing using capillary samples.

In June 2026, Danaher Corporation completed its acquisition of Masimo Corporation's non-invasive patient monitoring business for approximately $9.9 billion, adding advanced sensor technology and AI-enabled patient monitoring capabilities to Danaher's Diagnostics segment.

In May 2026, Roche entered into a definitive agreement to acquire PathAI, a company specializing in AI-powered digital pathology, aimed at strengthening Roche's digital pathology capabilities and advancing AI-enabled companion diagnostics and biomarker discovery.

These moves point to an industry where large diagnostics companies are increasingly acquiring AI and digital pathology capabilities rather than building them from scratch, while also expanding core testing menus to capture recurring reagent and consumable demand.

Key Insights from In Vitro Diagnostics Market Analysis

- Reagents and kits held the largest revenue share by product in 2025, at approximately 70%, reflecting their role as a recurring, consumable component of every diagnostic test performed.

- Molecular diagnostics is projected to register the highest CAGR by technology through 2031, at approximately 14.7%, driven by expanding use in infectious disease testing, oncology, and genetic testing.

- Infectious disease testing accounted for the largest application share in 2025, supported by the continued global burden of infectious disease and rising demand for rapid, accurate diagnosis.

- North America held the largest regional share in 2025, at approximately 39%, supported by advanced healthcare infrastructure and the presence of major IVD companies including Danaher, Abbott, Thermo Fisher Scientific, and Hologic.

- Asia-Pacific is the fastest-growing region, driven by expanding diagnostic infrastructure, rising healthcare expenditure, and growing pharmaceutical and biotechnology investment across China, Japan, India, and South Korea.

Key Players in the In Vitro Diagnostics Market

Leading companies in the in vitro diagnostics market are focused on product innovation, advanced diagnostic technologies, strategic partnerships, and geographic expansion to strengthen their market presence.

Regional Analysis and Growth Opportunities

North America leads the in vitro diagnostics market, supported by advanced healthcare infrastructure, high diagnostic testing volumes, substantial healthcare expenditure, and a concentration of leading IVD manufacturers. Strong adoption of molecular diagnostics, immunoassays, and laboratory automation, combined with continued investment in innovative diagnostic technologies, reinforces the region's leading position.

Asia-Pacific is the fastest-growing region, propelled by expanding diagnostic infrastructure, rising healthcare expenditure, and growing pharmaceutical and biotechnology industries across China, Japan, South Korea, and India. Increasing disease burden, rising diagnostic testing volumes, and expanding healthcare access are expected to further strengthen regional demand for advanced IVD solutions.

Europe, Latin America, and the Middle East & Africa complete the report's regional coverage, with growth supported by expanding diagnostic laboratory infrastructure and rising adoption of point-of-care testing.

Get a Custom Briefing on This Market for Your Business

Wissen Research's healthcare technology analysts are available to walk through findings specific to your market, region, or competitive set.

Need Insights Specific to Your Business? Request a Customized Version of This Report:

Market Segmentation Snapshot

The global in vitro diagnostics market is segmented across product, test type, technology, therapeutic area, end-user, and region:

- By Product:

- Instruments

- Reagents & Kits

- Software

- By Test Type:

- Diagnostic Laboratory Testing

- Point-of-Care Testing

- By Technology:

- Clinical Chemistry (Metabolic, Electrolyte, Liver, Lipid, Renal Panels, and Others)

- Immunoassay (ELISA, Chemiluminescence, Fluorescence Immunoassay, Rapid Tests, ELISPOT, and Others)

- Molecular Diagnostics (PCR, Sequencing, In-Situ Hybridization, Isothermal Nucleic Acid Amplification, Chips and Microarrays, Mass Spectrometry, and Others)

- Hematology

- Microbiology

- Coagulation

- Others

- By Therapeutic Area:

- Infectious Disease

- Cardiology

- Diabetes

- Oncology

- Nephrology

- Autoimmune Disease

- Drug Testing

- Others

- By End-User:

- Diagnostic Laboratory

- Hospital

- Home Care

- Others

- By Region:

- North America

- Europe

- Asia-Pacific

- Latin America

- Middle East & Africa

Frequently Asked Questions

Q: What is the size of the in vitro diagnostics market? 

A: The global in vitro diagnostics market is estimated at USD 117.39 billion in 2026 and is projected to reach USD 170.10 billion by 2031.

Q: What is the growth rate of the in vitro diagnostics market? 

A: The in vitro diagnostics market is projected to grow at a CAGR of 7.7% between 2026 and 2031.

Q: Which product segment holds the largest share of the in vitro diagnostics market? 

A: Reagents and kits held the largest share by product in 2025, at approximately 70%, driven by their role as a recurring, consumable component of every diagnostic test performed.

Q: Which technology segment is growing fastest in the in vitro diagnostics market? 

A: Molecular diagnostics is projected to register the highest CAGR by technology through 2031, at approximately 14.7%, driven by expanding use in infectious disease testing, oncology, and genetic testing.

Q: Which region leads the in vitro diagnostics market? 

A: North America held the largest share of the in vitro diagnostics market in 2025, at approximately 39%, while Asia-Pacific is the fastest-growing region through 2031.

Q: Who are the top players in the in vitro diagnostics market?

The Mississippi Gulf Coast serves up frights, family fun, and coastal charm for the spooky season

BILOXI, Miss., Sept. 17, 2026 /PRNewswire/ -- This Halloween, Coastal Mississippi is inviting visitors for a trip filled with fright to experience the Coast with the Ghosts. From hundreds of "witches" parading through historic downtowns to a 40,000-square-foot haunted warehouse, the Mississippi Gulf Coast trades sunbathers for skeletons and turns its beach towns into one long trick-or-treat trail.

Spanning 62 miles of scenic shorelines, this year's Halloween calendar of events brings 10 events to the destination. Whether travelers are planning a family getaway or an adults-only trip, here's where to find the fright this October in Coastal Mississippi:

- Terror on the Coast (Gulfport, Sept. 18–Oct. 31): The Coast's largest haunted attraction returns to its 40,000-square-foot warehouse with Hollywood-caliber sets, live actors and a hall of food trucks, vendors, and a full bar.

- Fall Fest at Biloxi Towne Green (Biloxi, Oct. 17): A free, family-friendly festival on the beach with local vendors, food trucks and a costume contest for kids and adults that's judged on creativity, humor, and scare factor.

- Seventh Annual Boo in the Bay Parade (Bay St. Louis, Oct. 17): A free, family-friendly parade featuring decorated golf carts, Jeeps and classic cars rolling through Old Town as costumed participants toss candy and Halloween trinkets to spectators.

- Moonlight Masquerade: Party from Planet X (Biloxi, Oct. 17): The Gulf Coast Center for Nonviolence's 16th annual gala transforms White Pillars Restaurant & Lounge into a retro-futuristic costume party, with live music, a silent auction, and proceeds benefiting survivors of domestic violence across South Mississippi.

- Candlelight: A Haunted Evening of Halloween Classics (Ocean Springs, Oct. 23): A string quartet performs candlelit renditions of scores from Halloween, Psycho, Ghostbusters and Beetlejuice at the Mary C. O'Keefe Cultural Arts Center. It's a must-see Halloween atmosphere without a single jump scare.

- Kroctoberfest '26 (Biloxi, Oct. 23): A free, family-friendly fall tradition at the Salvation Army Kroc Center Mississippi Gulf Coast, featuring trunk-or-treating, a costume contest, live music, food trucks, and community vendors.

- Boo Bash (Gulfport, Oct. 24): The City of Gulfport's free annual Halloween bash returns to the Sportsplex soccer fields for an evening of games, trunk-or-treating, and family-friendly fun.

- Witches Ride of Ocean Springs (Ocean Springs, Oct. 24): Nearly 500 witches trade brooms for decorated bikes, golf carts, and walking shoes for a parade through downtown Ocean Springs, with all proceeds supporting local animal welfare organizations.

- Bay St. Louis Witches Walk (Bay St. Louis, Oct. 24): Old Town Bay St. Louis fills with costumed "witches" for a morning of shopping specials, contests, and photo ops throughout the district's boutiques and galleries.

- Here Come the Mummies (Biloxi, Oct. 29): The self-described "Terrifying Funk from Beyond the Grave" band brings its horn-driven, high-energy funk-rock show to Studio A at IP Casino Resort & Spa.

- Brick or Treat at TrainTastic (Gulfport, Oct. 31): A LEGO-themed send-off to the season, combining Halloween costumes with hands-on building activities and make-and-take projects for families.

"Halloween in Coastal Mississippi has grown into one of our most anticipated seasons," said Judy Young, CEO of Coastal Mississippi Tourism. "Each of our communities across Jackson, Harrison and Hancock counties brings its own personality to the season, with celebrations and experiences you simply won't find anywhere else. We invite visitors to come for the Halloween fun, stay a few days and explore everything Coastal Mississippi has to offer, from our 62 miles of shoreline and incredible seafood to our attractions, arts and welcoming coastal communities. It's the perfect time to turn a Halloween celebration into a Coastal Mississippi getaway."

For more information on the countless ways to explore Coastal Mississippi this Halloween season, or to plan a trip today, please visit CoastalMississippi.com or follow @PlayCoastalMS on social media.

About Coastal Mississippi: Coastal Mississippi is the organization charged with promoting South Mississippi as a tourism and convention destination worldwide. Its mission centers on attracting ever-increasing numbers of leisure, convention, sports, and business travelers to the area. It is dedicated to maximizing the travel and tourism industry for South Mississippi. Visit CoastalMississippi.com to learn more.

SOURCE Coastal Mississippi

Share this article

DG Display Showcase Expands Global Project Capabilities with New Production Base

The planned 30,000+ sq. m. base will expand DG Display Showcase's manufacturing, engineering, R&D and global project delivery capabilities for larger and more complex retail space projects.

GUANGZHOU, China, Sept. 17, 2026 /PRNewswire/ -- DG Display Showcase, a customized display and retail space solution provider, is developing a new production base to support the next stage of its global business. With a planned gross floor area of more than 30,000 square meters, the base will bring manufacturing, R&D, engineering and customer experience functions into one integrated facility. The new base is designed to support larger flagship stores, multi-store rollouts and more complex retail environments for international brands.

Founded in 1999, DG Display Showcase has 27 years of experience in custom display and retail space solutions. The company has completed more than 9,380 brand store projects worldwide and handles more than 200 customized projects each year. Its team includes more than 180 engineering and craftsmanship professionals.

Projects Are Getting More Complex

DG Display Showcase serves projects across jewelry, watches, fragrance, luxury retail and museum display. As projects become larger and more customized, their requirements increasingly extend across engineering interfaces, brand standards, local installation conditions and tight opening schedules. Different materials, display systems, lighting, electrical and security features may also need to work together within the same project.

For international brands, project delivery also requires consistent execution across locations, close coordination between design and engineering, reliable production schedules, international logistics and installation support. These requirements can involve multiple teams and project stages, increasing the need for close coordination throughout the project lifecycle.

These requirements are shaping DG Display Showcase's plans for the new production base. The facility is being developed to connect design, engineering, manufacturing, verification and project delivery more closely, creating a more coordinated workflow for complex international retail projects.

One Base, More Capabilities

The new production base will include a Smart Manufacturing Center, an R&D and Design Center, a Global Display Experience Center and business and customer experience areas.

These functions are designed to work together across the project lifecycle. R&D and design teams can work closely with engineering teams on materials, structures, lighting and display solutions. Manufacturing teams can then work from the same project requirements, while verification and customer collaboration remain connected to the development process.

The Global Display Experience Center will also provide a space for customers to review materials, engineering solutions and finished display systems, and to discuss project requirements with DG teams.

The value of the new base comes from connecting design, engineering, manufacturing, verification and customer collaboration more closely. This structure is intended to create a more connected workflow from early design discussions through production and project delivery.

Design Must Work in Production

Complex retail design requires more than a strong visual concept. The design must also work through production, transportation and installation.

DG Display Showcase plans to strengthen its engineering work around complex metal structures, curved components, bent glass, precision assembly, integrated lighting and intelligent security systems.

The R&D and Design Center will help teams review structural feasibility, materials, hardware, lighting and installation requirements before production begins. This process can help turn design concepts into solutions that can be manufactured, transported and installed across different markets.

Quality Starts Before Shipment

International installation can create risks for large luxury retail projects. Site schedules can be tight. Multiple teams may work on the same project. Small issues can affect installation time and project progress.

DG Display Showcase plans to increase factory pre-assembly and verification as part of the new base's project workflow.

Teams can check structural connections, showcase joints, doors, lighting, hardware, electrical interfaces and installation points before shipment. Early checks can help identify issues while products are still at the factory.

For customers, this can mean fewer surprises at the installation site and more consistent results across multiple locations.

Building for Global Delivery

The new base also supports DG Display Showcase's wider move toward intelligent manufacturing and integrated project management. The company's 2026 development direction includes self-built facilities, intelligent manufacturing, AI-powered full-chain processes and digital twin models.

These initiatives are designed to improve coordination across the project lifecycle. The goal is to connect brand requirements, design, engineering, production, quality control and global delivery more closely.

For luxury brands, this creates a stronger foundation for flagship stores, chain-store projects, multi-brand spaces and museum display projects across different markets.

"Over the years, we have seen our customers' projects become larger, more customized and more international. These projects have raised the requirements for every stage of delivery, from design and engineering to manufacturing and installation. The new production base is our investment in the capabilities needed for this next stage. We are building the foundation to manage complex projects, maintain consistent quality and support customers across different markets," said Selina, Founder of DG Display Showcase.

Supporting the Next Stage

For DG Display Showcase, the new base represents a long-term investment in the engineering, manufacturing and delivery capabilities required for increasingly complex international retail projects.

About DG Display Showcase

Founded in 1999 and headquartered in Guangzhou, China, DG Display Showcase develops customized display and retail space solutions for jewelry, watches, fragrance, museums and luxury retail environments. With more than 27 years of industry experience and more than 9,380 completed brand store projects worldwide, the company provides services spanning design, engineering, manufacturing, logistics, installation support and after-sales service. DG Display Showcase works with international clients on customized display systems and one-stop retail solutions developed around individual brand and project requirements.

Media Contact:

Official website: https://www.degreefurniture.com/

Company Name: DG Master of Display Showcase Co.,Ltd

Email: [email protected]

WhatsApp: +86 13922429233

SOURCE DG Master of Display Showcase Co.,Ltd

Share this article

LEADING AMERICAN MANUFACTURER CONTINUES TO DELIVER ON $600 MILLION COMMITMENT, FUELING INCREASED PRODUCTION OF MICHELOB ULTRA AND CUTWATER

LOS ANGELES, Sept. 17, 2026 /PRNewswire/ -- Today, Anheuser-Busch [NYSE: BUD], a leading American manufacturer and maker of Michelob ULTRA, Busch Light, Budweiser, Bud Light, Cutwater Spirits and NÜTRL Vodka Seltzer, announced a $21 million investment in its Los Angeles and Mira Loma, California facilities. This investment will help Anheuser-Busch, the #1 fastest-growing supplier in total alcohol,1 fuel increased production of Michelob ULTRA and Cutwater and expand local manufacturing skills training.

Today's announcement is part of Anheuser-Busch's ongoing Brewing Futures initiative through which the company is investing $600 million in its U.S. operations across 2025 and 2026. The initiative builds on Anheuser-Busch's commitment to investing in people, breweries and communities by creating and sustaining manufacturing jobs, building the manufacturing workforce for the future, and strengthening manufacturing career opportunities for Veterans.

Brendan Whitworth, CEO, Anheuser-Busch said: "Anheuser-Busch is committed to supporting the communities where our employees live and work. Investments in facilities like Los Angeles and Mira Loma help us strengthen our operations while creating and sustaining jobs and continuing to drive economic growth throughout California. We're proud to continue investing in American manufacturing and in the hardworking Californians who help to produce America's most iconic beer and spirits brands every day."

This new $21 million investment in Anheuser-Busch's Southern California facilities help fuel production of Michelob ULTRA, the #1 top-selling and fastest-growing beer in America,2 while upgrading canning and bottling operations. It will also enhance production of Cutwater, the #1 spirits-based cocktail brand in the U.S.3, and Phorm Energy, a top 15 brand in total energy.4 Additionally, the investment will increase rail capacity, strengthening transportation capabilities and route to market.

Anheuser-Busch will also open a new technical skills training center inside the Los Angeles Brewery—one of 15 new centers nationwide—to upskill our operators and technicians in electrical and mechanical systems associated with brewery equipment. The company plans to upskill more than 90% of its manufacturing workforce across the U.S. over the next five years.

U.S. Representative Luz Rivas (CA-29) said: "Anheuser-Busch's investment in its Los Angeles brewery in Van Nuys demonstrates the company's longtime commitment to the San Fernando Valley and the greater LA area. Its upgraded operations, along with the new skills training, will help create and sustain jobs right here in Southern California. I'm grateful for Anheuser-Busch's continued investment in our workforce and our economy."

California State Senator Caroline Menjivar (D–San Fernando Valley) said: "Since 1954, the Anheuser-Busch Brewery in Van Nuys, has been a vital employer in Senate District 20. This additional $21 million investment shows Anheuser-Busch's continued commitment to its local operations building economic prosperity in Van Nuys and building California's manufacturing future. By coupling facility improvements with expanded technical skills training, Anheuser-Busch is creating real opportunities for Californians to advance into steady manufacturing careers. Anheuser-Busch's continued investment in their workers plays a part in strengthening the future of American manufacturing, right here in Southern California."

California State Assemblyman Jesse Gabriel (D-Encino) said: "I applaud Anheuser-Busch's commitment to continued investment in California and the San Fernando Valley. This $21 million investment will strengthen California's manufacturing sector, create pathways to long-term careers, support workers, and benefit our local economy."

Anheuser-Busch has proudly called Los Angeles home for over 70 years, investing $184 million in its Los Angeles and Mira Loma facilities since 2021, and remains committed to being a key economic driver on the West Coast. Hundreds of Californians are employed at these facilities, producing more than 50 Anheuser-Busch brands at the Los Angeles Brewery.

ABOUT ANHEUSER-BUSCH

At Anheuser-Busch, our purpose is to create a future with more cheers. For more than 165 years as a leading American manufacturer, we have delivered a legacy of brewing great-tasting, high-quality beers that have satisfied beer drinkers for generations. As the nation's top brewer, one of the fastest growing spirits companies, and an insurgent force in energy drinks, we drive economic prosperity nationwide through investments in our people, facilities, and communities. We are the only alcohol company that invests in the U.S. at this scale.

We make the nation's most iconic beers, ready-to-drink spirits and beyond beer brands, including Michelob ULTRA – America's #1 top-selling and fastest-growing beer – Busch Light, Budweiser, Bud Light, Stella Artois, Cutwater Spirits, NÜTRL Vodka Seltzer, BeatBox, industry-leading craft beers and non-alcohol beers like Michelob ULTRA Zero. We are guided by our commitment to the communities we call home and to the 65,000 hardworking Americans who bring our products to life. That's who we are. For more information, visit www.anheuser-busch.com or follow Anheuser-Busch on LinkedIn, X, Facebook, and Instagram.

1 Circana TUS MULC+ w/e 7/19/26

2 Circana TUS MULC+ Volume Sales w/e 7/19/26

3 Circana, $ Sales, YTD 07.19.26, TUS HB GEO

4 Circana Total US – MULC YTD Thru 8/30/2026

SOURCE Anheuser-Busch

Share this article

The article outlines when growing electrical demand may require a higher-capacity electrical panel for safe and reliable home operation.

KNOXVILLE, Tenn., Sept. 17, 2026 /PRNewswire/ -- The article explains that an electrical panel serves as the central point for distributing electricity throughout a home, but every panel has limits. As households continue to add modern technology, larger appliances, and new conveniences, many older electrical systems are being asked to handle more than they were originally designed to. Understanding electrical panel capacity helps homeowners recognize when it may be time to evaluate their existing system before problems develop.

According to the article, many homes were built when families relied on fewer electrical devices. Basic lighting, smaller kitchen appliances, and simpler heating and cooling systems placed far less demand on electrical systems than today's homes do. Modern lifestyles often include home offices, smart home devices, multiple entertainment systems, and larger HVAC equipment that increase overall electricity use throughout the day.

The HelloNation article notes that one of the most common reasons to consider increasing electrical panel capacity is the addition of new equipment. Installing an EV charger, converting to an electric range, adding a hot tub, or finishing a basement can significantly increase the amount of electricity a home requires. While each project may function properly on its own, the combined electrical demand can place added strain on an older electrical panel.

The article also discusses the importance of available breaker space. Homeowners planning renovations or appliance upgrades sometimes discover there are no open spaces left for additional circuit breakers. Although some situations have approved solutions, a full panel often signals that it is time to evaluate whether a larger electrical panel would better support both current needs and future home upgrades.

Repeated circuit breaker trips are another issue addressed in the article. While tripped breakers do not always mean a panel lacks sufficient capacity, they should not be ignored. The article explains that circuit breakers are designed to shut off power when conditions become unsafe or circuits become overloaded. If breakers trip frequently during normal household activities, a professional evaluation can determine whether additional panel capacity or other electrical improvements are needed.

The article emphasizes that planning for future electrical demand is often more practical than waiting until problems appear. Homeowners considering solar energy systems, battery storage, expanded living areas, workshops, or additional electrical appliances benefit from evaluating the electrical panel's capacity during the planning process. Taking this step early may reduce delays and help avoid repeated electrical modifications later.

The HelloNation article also explains that older electrical panels may continue to function even when they no longer meet the capacity expected for modern homes. While age alone does not require replacement, a professional evaluation can determine whether an existing electrical system continues to meet current safety expectations, electrical codes, and household usage. This is especially valuable for homes that have undergone several renovations over the years.

Throughout the article, Electrical Expert Gerald Talbot explains that understanding how household electrical demand is changing allows homeowners to prepare their electrical systems for future growth while reducing unnecessary strain on existing equipment. The article encourages homeowners to view electrical panel evaluations as part of responsible long-term home planning rather than waiting until interruptions become more frequent.

" When an Electrical Panel Needs More Capacity" features insights from Gerald Talbot, an Electrical Expert in Knoxville, Tennessee, on HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

Denarius Holding Group Announces Long-Term Investment in Venezuela's CEMA Oil Field

U.S.-incorporated company deploys transparent international capital and American operational standards to develop a major upstream asset under the current U.S. regulatory framework.

MIAMI, Sept. 17, 2026 /PRNewswire/ -- Denarius Holding Group Inc., a U.S.-incorporated energy holding company headquartered in Florida, announced on September 16 a long-term investment in the development of the CEMA Oil Field (formerly Petrokariña Oil Field) in Anzoátegui State, Venezuela, through its principal partnership in Minerosol Group C.A., which has executed the Hydrocarbons Production Participation Contract (Contrato de Participación para la Producción de Hidrocarburos - CPPH) with Petróleos de Venezuela, S.A. (PDVSA). The company notes that this CPPH relates specifically to the CEMA Oil Field in eastern Venezuela and is distinct from the separate Petrokariña Joint Venture operating in western Venezuela.

The investment represents one of the first meaningful private-sector commitments in Venezuela's energy sector of this new era — deploying transparent international capital through a U.S. corporate vehicle, executed to American operational and compliance standards, under the current U.S. regulatory framework. The project is expected to support the rehabilitation of mature oilfield infrastructure, production optimization, well interventions, and the application of international operational, environmental, and safety standards.

The project encompasses approximately 100 million barrels of recoverable reserves and is governed by a 20-year CPPH agreement with an additional 20-year extension option, providing the contractual certainty required to support multi-decade capital investment and sustainable field development.

The development plan contemplates approximately US$400 million in phased investment over the initial 20-year term. Current production at the CEMA Oil Field is approximately 400 barrels of oil per day, with the development program targeting production of approximately 9,870 barrels per day through field rehabilitation, operational improvements, and enhanced production techniques.

"This investment reflects our confidence that responsible private-sector participation — structured through a U.S. corporate vehicle and executed to American operational and compliance standards — can contribute to the sustainable development of Venezuela's energy sector," said Zehra Zeynep Dereli, Vice President, Denarius Holding Group Inc. "The current U.S. regulatory framework provides the clarity that allows responsible American companies to evaluate opportunities of this scale while maintaining the highest standards of compliance and governance."

"At Denarius, we are committed to conducting our business with integrity, transparency, safety, and rigorous regulatory compliance. Our objective is to deliver American operational excellence while building lasting partnerships that create sustainable value for our clients, employees, and the communities where we operate."

Denarius Holding Group Inc. developed the project through an extensive legal, commercial, and compliance review, working closely with experienced U.S. sanctions counsel and regulatory advisors to ensure its activities are conducted in accordance with applicable U.S. laws and regulations. Compliance has been integrated into every stage of project planning and execution and remains a fundamental component of the company's operating model.

The project is expected to support the modernization of critical oilfield infrastructure while strengthening local operational capabilities and creating opportunities for contractors, service providers, and skilled technical personnel throughout the project's lifecycle.

"This investment represents an important milestone for our company and the beginning of an enduring commitment to responsibly developing energy resources in Venezuela," Dereli added. "Our focus is on executing this project safely, responsibly, and transparently while maintaining the highest standards of corporate governance and environmental stewardship."

Additional details regarding the scope of work will be disclosed as appropriate and in accordance with applicable commercial obligations and regulatory requirements.

Denarius Holding Group Inc. conducts its activities in accordance with applicable U.S. laws and regulations.

About Denarius Holding Group Inc.

Denarius Holding Group Inc. is a U.S.-incorporated energy holding company headquartered in Florida, with operating interests in upstream oil and gas development and oilfield services in international markets. Its principal shareholder is Çan2 Termik A.Ş. (BIST: CANTE), a publicly listed Turkish company subject to Turkish Capital Markets Board disclosure and audited financial reporting. The Group's U.S. affiliate, Denarius Pumping Services LLC, delivers specialized cementing, well services, and field engineering capabilities to the Group's projects. Denarius combines U.S. corporate governance, American operational standards, disciplined project execution, technical expertise, and rigorous compliance practices to support the responsible development of energy infrastructure in complex operating environments. Denarius Holding Group Inc. is dedicated to fostering enduring partnerships while upholding the highest standards of safety, transparency, environmental stewardship, regulatory compliance, and corporate governance.

SOURCE Denarius Holding Group Inc

Share this article

Equity Insider News Commentary

VANCOUVER, BC, Sept. 17, 2026 /PRNewswire/ -- Silver is running its sixth consecutive annual structural deficit, and the price has followed. Spot silver traded around $65 an ounce through mid-August and was assessed at $66.41 on August 31. That alone would be the story in most years. The more interesting arithmetic is happening one layer down, in the polymetallic deposits where silver arrives alongside zinc, lead and copper. When base metal by-product credits are subtracted from total costs, the all-in sustaining cost of the silver itself can go negative, which is to say the base metals pay for the mine and the silver is margin. That is not a pricing curiosity. It changes which deposits are financeable and in what order. Active Companies from around the markets with current developments this week include: Honey Badger Silver Inc. (TSXV: TUF) (OTCQB: HBEIF) (FSE: 1QA) (Tradegate: 1QA), Hecla Mining Company (NYSE: HL), Pan American Silver Corp. (NYSE: PAAS), Vizsla Silver Corp. (NYSE American: VZLA), and Coeur Mining, Inc. (NYSE: CDE).

The deficit itself is well documented and has been persistent rather than cyclical. Industrial demand, led by solar and electronics, has grown faster than mine supply for six straight years, and silver is mostly produced as a by-product of other metals rather than from primary silver mines, which means the supply response to a higher silver price is weaker than in most commodities. A copper miner does not open a pit because silver went up.

That structure is exactly why polymetallic deposits behave differently from primary silver deposits at this point in the cycle. A deposit carrying meaningful zinc, lead and copper alongside its silver generates revenue from metals whose own markets are tight, and those revenues are credited against the cost of producing the silver. The reported cash cost per silver ounce falls, sometimes below zero, and the project's sensitivity to the silver price changes shape entirely.

The second variable is what has already been spent. Most projects reaching a preliminary economic assessment are proposing to build everything: mill, camp, tailings facility, road, power. A project where a mill, an airstrip and kilometres of underground development already exist is answering a different capital question, and the study that describes it should be read differently as a result.

Honey Badger Silver Announces Positive Preliminary Economic Assessment for the PC Silver Mine; Sees Significant Silver Plus Critical Minerals Production

- A 22-year mine life on an updated Mineral Resource Estimate containing 11.63 million tonnes of Measured and Indicated resources grading 424 g/t AgEq and 8.47 million tonnes of Inferred resources grading 492 g/t AgEq.

- Average annual production of approximately 10.7 million ounces of silver equivalent over the first seven years, comprising roughly 3.7 million ounces of silver plus 157 million pounds of zinc, 118 million pounds of lead and 2.2 million pounds of copper.

- All-in sustaining cost of negative US$22 per silver ounce in the long-term consensus pricing case, net of by-product credits, and negative US$36 per ounce at spot pricing.

- After-tax NPV of $1.2 billion at an 8% discount rate with a 29% IRR and 3.1-year payback in the long-term consensus case; $1.8 billion and 38% at spot pricing.

- Capital costs of $197 million for mine development, mill refurbishment, tailings and other onsite work, plus $205 million for a 170 km all-season road, $174 million indirect and $92 million contingency.

Honey Badger Silver Inc. (TSXV: TUF) (OTCQB: HBEIF) (FSE: 1QA) (Tradegate: 1QA) announced the results of an updated Preliminary Economic Assessment and updated Mineral Resource Estimate for its 100%-owned PC Silver Mine, historically known as Prairie Creek, in the Northwest Territories. All amounts are in Canadian dollars unless otherwise stated. The PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves, and there is no certainty that the PEA will be realized.

The study contemplates an underground operation mining approximately 2,400 tonnes per day, with dense media separation upgrading and milling at approximately 1,500 tonnes per day post-DMS over 22 years. Mined grade before DMS is 112 g/t silver with 6.1% lead, 8.5% zinc and 0.25% copper, rising to a mill head grade of 173 g/t silver with 9.4% lead, 12.8% zinc and 0.39% copper after upgrading. Life-of-mine payable production is approximately 56.1 million ounces of silver alongside 2,080 million pounds of lead, 2,577 million pounds of zinc and copper.

The negative sustaining cost figure is the number that will draw attention, and it is worth stating precisely what it is. All-in sustaining cost is a non-GAAP measure, and the negative figures are reported net of by-product credits. The zinc, lead and copper revenue exceeds the total cost of the operation, so the cost attributable to each silver ounce computes below zero. It is a legitimate and widely used presentation in polymetallic mining, and it is also entirely dependent on base metal prices holding. At weaker zinc, lead and copper prices the same mine has a positive silver cash cost.

"Second, PC Silver is an existing mine, which was built in the early 1980's, with significant capital already invested, extensive existing infrastructure, key permits in place and strong relationships with Indigenous communities, territorial and federal governments and other partners. We are advancing a significantly developed asset with decades of hard work and capital investment already behind it," commented Chad Williams, Executive Chairman of Honey Badger Silver.

That existing-asset argument is the reason the capital line reads the way it does. The site hosts a historic mill, an airstrip and approximately five kilometres of underground workings, and the all-season road is described as an upgrade to an existing winter road rather than a new corridor. The Company holds Impact and Benefit Agreements with the Nahɒą Dehé Dene Band and Łíídlįį Kų́ę́ First Nation and a Benefit Agreement with Acho Dene Koe First Nation, and a federal National Trade Corridors Fund contribution of up to $25 million toward the road has previously been announced and remains subject to drawdown conditions.

Williams also flagged what the study deliberately leaves out. No economic value has been attributed to germanium, antimony or tungsten, nor to recent Canadian tax incentives, and the Company has said it will evaluate a staged, lower-capital initial production start that could generate cash flow earlier before ramping toward the scenario in the PEA. The board has authorised the next stage of engineering with a Feasibility Study targeted for completion in the second quarter of 2027. On financing, Williams referred to inbound interest from smelters and off-takers, debt providers, government agencies and infrastructure investors, and two unsolicited expressions of interest for turnkey project financing. None of that is a commitment, no financing has been arranged, and no production decision has been made.

Read this and more news from around the sector at: https://Equity-Insider.com.

In other industry developments and happenings in the market this week include:

Hecla Mining Company (NYSE: HL) is the largest silver producer in the United States and the clearest live illustration of what by-product economics do to margin. It reported 231 million ounces of silver reserves at the end of 2025, guided 2026 silver production of 15.1 million to 16.5 million ounces, and produced 4.2 million ounces in the second quarter of 2026. Chief Executive Rob Krcmarov has described the Company as accelerating investment, with the 2026 exploration and pre-development budget raised to $55 million.

The balance sheet moved in the same direction, with the last $263 million of senior notes redeemed in April 2026 and the revolving credit facility undrawn. Hecla operates Greens Creek, Lucky Friday and Keno Hill, all polymetallic, which is why its reported silver costs sit so far below the prevailing price. It is a long-established multi-mine producer at a completely different stage and scale from a company completing a PEA, and is referenced as sector context rather than as a comparable.

Pan American Silver Corp. (NYSE: PAAS) produced 22.8 million ounces of silver in 2025 and has guided 25 million to 27 million ounces for 2026, with the integration of the Juanicipio operation supporting a stronger production profile into a tightening market. It is the scale benchmark for the primary silver sector in the Americas.

Pan American is included because its guidance is one of the few reliable public read-throughs on whether primary silver supply is actually responding to the price. An increase of two to four million ounces across a portfolio of that size, against a market running a projected 67 million ounce deficit, is a useful measure of how slowly mine supply moves even when the incentive is obvious.

Vizsla Silver Corp. (NYSE American: VZLA) is the closest developer analogue in this group. Its Feasibility Study on the Panuco project in Mexico returned an after-tax net present value of approximately US$1.8 billion and an internal rate of return of 111% at a silver price of $35.50 per ounce, and the Company has reported holding more than US$450 million in cash alongside a 60,000 metre district drill program.

Two things are worth drawing from it. The first is that a study result of that order was generated at a silver price well below where the metal has traded through 2026, which is a reminder of how much of the current enthusiasm rests on price assumptions rather than on rock.